Stratford biotech company Oncogeni has been bought out in a £5.5 million deal by listed firm Roquefort Therapeutics. Oncogeni was founded by Nobel Laureate Professor Sir Martin Evans and has developed two families of innovative cell and oncology medicines.
Roquefort Therapeutics is headquartered in London and is focused on developing drugs in the high-value and high-growth oncology sector.
As a result of the deal, it has also admitted an additional 57.2 million shares onto the London Stock Exchange's main market following a shares placing and fundraise worth £1 million.
